Breaking News, Collaborations & Alliances

Debiopharm, NetTargets Partner to Advance Next-Gen ADCs

Will collaborate to progress the discovery of novel, synergistic drug combinations.

Author Image

By: Charlie Sternberg

Associate Editor

Debiopharm, a privately-owned biopharmaceutical company, has entered a strategic research collaboration with NetTargets, a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This alliance unites NetTargets’ sophisticated artificial intelligence (AI) platform with Debiopharm’s proprietary M...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters